Showing results (141-150 of 154) with videos related to

Sort By:
Pageof 16
Cancer|June 16, 2018
Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancerHanna K Sanoff, Richard M Goldberg, Anastasia Ivanova, et al.
Cancers|April 3, 2021
Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER"Niamh M Keegan, Simon J Furney, Janice M Walshe, et al.
The Lancet. Oncology|November 12, 2013
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trialJohn C Araujo, Géralyn C Trudel, Fred Saad, et al.
Cancers|September 28, 2021
Circulating Tumour Cell Numbers Correlate with Platelet Count and Circulating Lymphocyte Subsets in Men with Advanced Prostate Cancer: Data from the ExPeCT Clinical Trial (CTRIAL-IE 15-21)Brian Hayes, Lauren Brady, Gráinne Sheill, et al.
Nano Letters|June 19, 2018
Electronic Structure and Enhanced Charge-Density Wave Order of Monolayer VSe2Jiagui Feng, Deepnarayan Biswas, Akhil Rajan, et al.
International Journal of Oncology|November 20, 2013
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart reviewWilliam K Oh, David McDermott, Camillo Porta, et al.
Therapeutic Advances in Medical Oncology|August 7, 2019
Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trialGiuseppe Gullo, Alex J Eustace, Alexandra Canonici, et al.
The Lancet. Oncology|March 29, 2023
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
BMC Health Services Research|May 9, 2025
Disruption to diabetes and hypertension care during the COVID-19 pandemic in Latin America and the Caribbean and mitigation approaches: a scoping reviewOluwabunmi Ogungbe, Samira Barbara Jabakhanji, Roopa Mehta, et al.
The New England Journal of Medicine|June 4, 2019
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate CancerIan D Davis, Andrew J Martin, Martin R Stockler, et al.
Pageof 16